Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s earnings release is anticipated by WallStreet on March, 14, Faxor reports. Analysts predict 600.00 % diference or $-0.10 from the $0.02 EPS from 2018. -33.33 % EPS growth is what analysts predict. $-0.15 earnings per share was reported for previous quarter. Ticker’s shares touched $3.98 during the last trading session after 2.58% change.Brainstorm Cell Therapeutics Inc. has 157,635 shares volume, 140.23% up from normal. BCLI is downtrending and has moved 25.37% since February 18, 2018. BCLI underperformed the S&P500 by 25.37%.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others.The firm is valued at $82.42 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.Currently it has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

For more Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news released briefly go to: Seekingalpha.com, Globenewswire.com, Prnewswire.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” released on October 29, 2018, “FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis – GlobeNewswire” on December 17, 2018, “BrainStorm Cell Therapeutics’ Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients – PR Newswire” with a publish date: March 28, 2018, “Your Daily Pharma Scoop: Sorrento Sell-Off, Bluebird/Celgene Agreement, Edge Therapeutics’ Setback – Seeking Alpha” and the last “Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings, IPOs (Oct. 28-Nov. 3) – Benzinga” with publication date: October 27, 2018.